Valproate is an effective antiseizure medicine, but it carries some of the most important reproductive risks of any medicine used for epilepsy. Those risks affect treatment decisions for women and girls who can become pregnant, and newer UK precautions also apply to men who may father children.
Valproate may appear on prescriptions as sodium valproate, valproic acid or valproate semisodium, and under brand names including Epilim, Episenta and others. The reproductive-safety rules apply to valproate-containing medicines, not just one brand.
Why valproate is still used
Valproate can be highly effective for several epilepsy syndromes and seizure types, including some generalised epilepsies where alternative medicines may not provide equivalent seizure control.
This creates a genuine clinical balance. For some people, avoiding valproate is possible and safer. For others, alternative treatments fail, are not tolerated or do not control seizures adequately.
The purpose of modern restrictions is therefore not to pretend valproate has no place in epilepsy treatment. It is to prevent avoidable reproductive exposure while ensuring that people who genuinely need valproate can still receive effective treatment.
Current UK prescribing restrictions
Current MHRA guidance states that valproate should only be started in a new patient aged under 55 years — male or female — when two specialists independently agree and document that there is no other effective or tolerated treatment, or that there are compelling reasons why the reproductive risks do not apply.
These measures were introduced because reproductive harm is not limited to pregnancy exposure alone.
For men already taking valproate, the requirement for review by two specialists does not apply in the same way, but reproductive-risk counselling and precautionary contraception advice remain important.
Women and girls who can become pregnant
Valproate must not be prescribed to a woman or girl able to have children unless the conditions of the Pregnancy Prevention Programme are followed.
The programme is designed to make sure the person understands the reproductive risks, receives regular specialist review and uses highly effective contraception unless there are compelling reasons why pregnancy is not possible.
An Annual Acknowledgement of Risk Form is used as part of the programme.
What is the risk of birth defects?
Current MHRA guidance states that around 1 in 9 babies — approximately 11% — exposed to valproate during pregnancy will have a major congenital malformation.
Reported malformations include neural-tube defects such as spina bifida, abnormalities affecting the face and skull, limbs, heart, kidneys, urinary tract and other organs.
The risk is considerably higher than the background risk of major congenital malformations in the general population.
Neurodevelopmental effects are also a major concern
Valproate exposure during pregnancy is associated not only with structural birth defects but with developmental and neurodevelopmental problems.
Regulatory reviews have reported developmental disorders in a substantial proportion of children exposed in utero. These can include delayed development, learning and cognitive difficulties, language problems and increased rates of neurodevelopmental diagnoses.
The exact outcome for an individual child cannot be predicted from exposure alone, but the population-level signal is strong enough to justify strict prevention measures.
The risk is dose related — but there is no known completely safe pregnancy dose
Studies have generally found higher reproductive risk with higher valproate doses. However, a lower dose should not be described as risk-free.
If valproate must be continued during pregnancy for epilepsy because there is no suitable alternative, specialist teams aim to use the lowest effective dose that maintains seizure control.
The important phrase is effective dose. Reducing the dose to a level that causes breakthrough seizures is not a successful safety strategy.
Valproate polytherapy can carry additional risk
Pregnancies exposed to more than one antiseizure medicine can be harder to interpret because risks depend on the specific combination.
Valproate-containing combinations have historically been associated with higher rates of congenital malformations than many non-valproate regimens.
Where clinically possible, medication plans are reviewed before conception rather than after pregnancy begins.
Folic acid does not make valproate safe in pregnancy
Folic acid remains an important part of preconception care, particularly because neural-tube development begins very early in pregnancy.
However, folic acid should not be presented as an antidote to valproate teratogenicity. Available evidence does not show that folic acid prevents the full range of congenital malformations or neurodevelopmental effects associated with valproate exposure.
The dedicated Preconception Planning, Folic Acid and Epilepsy page explains current UK folic-acid advice in more detail.
If someone taking valproate wants to become pregnant
The first step is specialist review before contraception is stopped.
The specialist can assess whether another antiseizure medicine could provide adequate seizure control, whether a gradual transition is appropriate and whether the new treatment has been shown to work before conception.
A medication change may take months. Pregnancy planning should therefore begin early where possible.
Do not stop valproate suddenly
This is one of the most important safety messages.
Valproate should not be stopped abruptly without specialist advice, even when someone discovers they are pregnant.
Sudden withdrawal can cause seizure recurrence, seizure clusters, bilateral tonic-clonic seizures or status epilepticus. Those events can themselves create serious risk for the pregnant person and pregnancy.
If pregnancy occurs while taking valproate
A person who becomes pregnant while taking valproate should contact their specialist epilepsy team, GP or maternity service urgently.
The aim is prompt expert review — not panic and not abrupt self-discontinuation.
The team will review seizure history, dose, epilepsy syndrome, previous treatment failures and whether a safer effective alternative can be used.
Prenatal assessment cannot rule out every valproate-related effect
Ultrasound and other prenatal tests may identify some structural malformations, but they cannot predict all later developmental or cognitive effects.
This is another reason prevention of avoidable exposure before conception is more effective than relying on pregnancy screening after exposure has occurred.
Why the Pregnancy Prevention Programme matters
The programme exists because a pregnancy can begin before someone realises it has happened, and major embryonic development occurs early.
The programme therefore combines counselling, regular review and highly effective contraception rather than relying only on advice given after pregnancy is confirmed.
Valproate does not usually make hormonal contraception ineffective
Valproate is not a significant enzyme-inducing antiseizure medicine and does not normally reduce hormonal contraceptive effectiveness in the way carbamazepine, phenytoin or phenobarbital can.
However, the Pregnancy Prevention Programme has stricter contraception requirements than simply asking whether a contraceptive is pharmacologically compatible.
The dedicated Antiseizure Medicines and Contraception page explains enzyme-inducing interactions and highly effective contraceptive methods.
What about fertility in women?
Valproate has been associated with endocrine and reproductive effects, including menstrual disturbance, weight change, hyperandrogenism and features resembling polycystic ovary syndrome in some people.
These effects are not universal, and infertility should not be assumed simply because someone takes valproate.
Changes in menstrual pattern or concerns about fertility deserve clinical review rather than being automatically attributed to epilepsy or medication.
Male fertility can also be affected
Valproate has been associated with impaired male fertility, including changes in sperm count, motility or morphology in some studies and clinical reports.
These effects may be reversible after treatment is changed or stopped, but the evidence is not identical for every patient.
Men with fertility concerns should discuss them with their specialist rather than stopping valproate without supervision.
Newer concern: paternal exposure around conception
UK regulatory advice now also addresses possible risk when a man takes valproate around the time of conception.
A retrospective observational study found a possible increase in neurodevelopmental disorders among children fathered by men treated with valproate in the three months before conception compared with children of men treated with lamotrigine or levetiracetam.
In the study used by regulators, roughly 5 in 100 children fathered by men taking valproate had a neurodevelopmental disorder compared with around 3 in 100 in the comparison groups.
This study does not prove that valproate caused the difference. The MHRA nevertheless introduced precautionary measures because the potential effect concerns child development.
Current UK advice for men taking valproate
As a precaution, the MHRA recommends that male patients taking valproate use effective contraception during treatment and for at least three months after stopping treatment.
The advice refers to condoms together with contraception used by the female sexual partner.
Men are also advised not to donate sperm during treatment and for three months after stopping valproate.
The three-month period is intended to allow one sperm-development cycle without valproate exposure.
This paternal risk is not equivalent to maternal pregnancy exposure
The possible paternal risk is substantially smaller and less certain than the well-established risks from valproate exposure during pregnancy.
It is important not to collapse the two into one number or present the paternal finding as proven causation.
The maternal pregnancy risks are supported by decades of registry and observational evidence. The paternal advice is precautionary and based on a more limited evidence base.
Men should not stop valproate because they want to father a child
The correct response is specialist review.
If a man taking valproate is planning to father a child, the epilepsy team can consider whether another medicine could provide equivalent seizure control and whether a gradual change is appropriate.
For some people, changing treatment may create a greater immediate seizure risk than continuing valproate.
Why the rules changed for people under 55
The current UK under-55 restrictions reflect a broader regulatory approach to reproductive harm.
New valproate treatment in people younger than 55 now requires independent agreement from two specialists that no other effective or tolerated treatment exists, or that there are compelling reasons the reproductive risks do not apply.
This applies to new treatment in both males and females.
What happens after age 55?
The special two-specialist initiation rule is specifically focused on people under 55 because reproductive risks are the main concern.
Valproate prescribing after that age still requires ordinary clinical assessment of benefits, risks, interactions and adverse effects.
Age alone does not make valproate automatically appropriate or automatically inappropriate.
Valproate and breastfeeding
Pregnancy risk and breastfeeding risk should not be treated as the same thing.
Valproate transfer into breast milk is generally low, and infant blood concentrations are usually low or undetectable. Breastfeeding is therefore often possible when valproate is clinically required.
The dedicated Breastfeeding and Antiseizure Medicines page covers lactation exposure and infant monitoring separately.
Risk communication needs context
People taking valproate should receive clear numerical information rather than vague phrases such as “there may be a small risk”.
At the same time, numbers must be explained accurately. An 11% congenital-malformation risk does not mean an 89% guarantee of no valproate-related effect, because developmental outcomes are a separate category and some children can be affected in more than one way.
Likewise, the paternal 5-in-100 versus 3-in-100 observational result should not be described as proof that valproate causes neurodevelopmental disorders through paternal exposure.
The decision is different for every epilepsy
Valproate can be particularly effective for some generalised epilepsies, including syndromes where other medicines may be less effective or may worsen certain seizure types.
A reproductive-safety discussion therefore needs to include the person’s actual epilepsy syndrome and previous response to treatment, not just a list of drug risks.
When another medicine is substituted
Switching from valproate to another medicine is not risk-free. The replacement medicine can cause adverse effects, fail to control seizures or interact with contraception and other treatment.
A planned transition usually involves gradual dose changes and observation of seizure control rather than a sudden switch.
Questions worth asking at a valproate review
- Why is valproate being used for my epilepsy?
- Which alternatives have already been tried or considered?
- What would the seizure risk be if treatment changed?
- Do the current under-55 prescribing rules apply to me?
- Do I need the Pregnancy Prevention Programme?
- Is my contraception considered highly effective?
- What should I do if I want to become pregnant?
- What should I do if pregnancy occurs unexpectedly?
- If I am male, what is the current advice about contraception and fathering a child?
- Could valproate be affecting fertility?
The central message
Valproate carries substantial and well-established reproductive risk when taken during pregnancy, which is why UK prescribing is tightly restricted and a formal Pregnancy Prevention Programme applies to women and girls who can become pregnant.
There is also newer precautionary advice for men because of a possible association between paternal valproate exposure around conception and neurodevelopmental disorders in children.
These risks are serious, but they do not mean valproate should be stopped without medical supervision. For some people with epilepsy, valproate remains the treatment that provides the best seizure control.
The safest approach is specialist-led treatment, clear reproductive counselling, effective contraception where required and planned medication review before conception.
Related pages: Hormones, Contraception & Pregnancy · Preconception Planning, Folic Acid and Epilepsy · Antiseizure Medicines and Contraception · Breastfeeding and Antiseizure Medicines · Treatment Options
Sources and further reading
MHRA — Valproate: reproductive risks
MHRA — Updated valproate safety and educational materials, June 2025
MHRA — Valproate use in men: precautionary contraception advice
MHRA — Two-specialist initiation requirements and current male-patient rules
NICE NG217 — Treatment, safety, monitoring and withdrawal
NICE NG217 — Information and support: reproductive health
Evidence checked: September 2026.